Castration-resistant Prostate Cancer
📧 Sign up to get email alerts when something new happens for Castration-resistant Prostate Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2024-12-04Clinical Trial Update: Management of Castration-Resistant Prostate Cancer with Oligometastases [Phase 2, Phase 3]
This document reports an ongoing Phase 2/Phase 3 clinical trial evaluating management of castration-resistant prostate cancer with oligometa…
-
CLINICAL_TRIALS research · 2024-11-27Clinical Trial Update: 18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer [Phase 4]
A Phase 4 trial evaluating whether 18F-Fluciclovine PET/CT can predict outcomes of 177Lu-PSMA-617 therapy in prostate cancer patients. The s…
-
CLINICAL_TRIALS research · 2024-11-26Clinical Trial Update: Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC [Phase 2]
Phase II randomized trial comparing patient-specific adaptive dosing versus continuous dosing of Abiraterone acetate or Enzalutamide for met…
-
CLINICAL_TRIALS trial_result · 2024-11-22Clinical Trial Update: Biomarker-driven Intermittent Docetaxel in Metastatic Castration-resistant Prostate Cancer [Phase 2]
A Phase 2 biomarker-driven intermittent docetaxel trial in metastatic castration-resistant prostate cancer has been terminated.
-
CLINICAL_TRIALS trial_result · 2024-11-21Clinical Trial Update: A Registry Based Study Evaluating Overall Survival and Treatment Length in mCRPC Patients Treated With Enzalutamide in Sweden
A registry-based study in Sweden evaluates overall survival and treatment duration in metastatic castration-resistant prostate cancer patien…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-11-21Clinical Trial Update: A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients [Phase 1, Phase 2]
This Clinical Trial Update reports on a completed Phase 1/2 study of MDV3100 (enzalutamide) in prostate cancer to evaluate safety, tolerabil…
-
CLINICAL_TRIALS trial_result · 2024-11-21Clinical Trial Update: Long-Term Specified Drug Use-Results Survey for Xtandi Capsule
Clinical trial update reporting long-term usage results for Xtandi (enzalutamide) in castration-resistant prostate cancer.
-
CLINICAL_TRIALS trial_result · 2024-11-21Clinical Trial Update: A Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy [Phase 2]
Phase 2 study updating safety observations of enzalutamide in men with progressive castration-resistant prostate cancer previously treated w…
-
CLINICAL_TRIALS trial_result · 2024-11-20Clinical Trial Update: Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects [Phase 2]
Phase 2 clinical trial of pembrolizumab in metastatic castration-resistant prostate cancer, with or without DNA damage repair defects; the s…
-
CLINICAL_TRIALS trial_result · 2024-11-20Clinical Trial Update: Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC)
This is an observational cohort study update for castration-resistant prostate cancer, including metastatic cases, registered as NCT02380274…
-
CLINICAL_TRIALS research · 2024-11-19Clinical Trial Update: A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors [Phase 1]
Phase 1 study evaluating XL092 as a single-agent and combination therapy for solid tumors, including renal cell carcinoma, hormone receptor-…
-
CLINICAL_TRIALS trial_result · 2024-11-08Clinical Trial Update: Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer [Phase 1]
Phase 1 study evaluating safety, tolerability, pharmacokinetics, and anti-tumor activity of a Thorium-227 labeled antibody-chelator conjugat…
-
CLINICAL_TRIALS trial_result · 2024-11-07Clinical Trial Update: Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer [Phase 2]
Phase 2 results for onvansertib in combination with abiraterone and prednisone in adults with metastatic castration-resistant prostate cance…
-
CLINICAL_TRIALS research · 2024-10-29Clinical Trial Update: RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment Failure [Phase 1, Phase 2]
A Phase 1/2 clinical trial update evaluating RC48 monotherapy or RC48 in combination with Envafolimab for metastatic castration-resistant pr…
-
FDA approval · 2024-10-28FDA Approved: ABIRATERONE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved Hikma Pharmaceuticals USA Inc.'s supplemental application for Abiraterone acetate under an ANDA.
-
CLINICAL_TRIALS trial_result · 2024-10-23Clinical Trial Update: A Study Evaluating HC-1119 Single-Dose Pharmacokinetics and Effect of Food on Its Pharmacokinetics [Phase 1]
A Phase 1 study evaluating HC-1119 single-dose pharmacokinetics and the effect of food on its pharmacokinetics in metastatic castration-resi…
-
CLINICAL_TRIALS research · 2024-10-21Clinical Trial Update: European Observational Study of Enzalutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
European observational study evaluating enzalutamide in metastatic castration-resistant prostate cancer has completed. The study's findings …
-
CLINICAL_TRIALS trial_result · 2024-10-16Clinical Trial Update: Checkpoint Inhibitors and SBRT for MCRPC [Phase 2]
A Phase 2 trial evaluating checkpoint inhibitors in combination with stereotactic body radiotherapy for metastatic castration-resistant pros…
-
CLINICAL_TRIALS trial_result · 2024-10-16Clinical Trial Update: 68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer [Phase 2]
This update reports Phase 2 results for the diagnostic imaging agent 68Ga-PSMA-11 PET in diagnosing metastatic castration-resistant prostate…
-
CLINICAL_TRIALS trial_result · 2024-10-10Clinical Trial Update: Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC [Phase 1, Phase 2]
Completed Phase 1/2 dose-escalation and efficacy study evaluating LAE001 with prednisone and afuresertib in metastatic castration-resistant …
-
CLINICAL_TRIALS trial_result · 2024-10-09Clinical Trial Update: Study of Docetaxel Combined with Cirmtuzumab in Metastatic Castration Resistant Prostate Cancer [Phase 1]
A Phase 1 trial evaluating the combination of docetaxel and cirmtuzumab in metastatic castration-resistant prostate cancer has been terminat…
-
CLINICAL_TRIALS trial_result · 2024-09-27Clinical Trial Update: Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC)
Pfizer-sponsored head-to-head trial in chemotherapy-naïve metastatic castration-resistant prostate cancer comparing enzalutamide to abirater…
-
CLINICAL_TRIALS research · 2024-09-27Clinical Trial Update: Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer [Phase 2]
This update describes a Phase 2 trial evaluating sequencing of Radium-223 and Docetaxel for symptomatic bone-only metastatic castration-resi…
-
CLINICAL_TRIALS trial_result · 2024-09-26Clinical Trial Update: Combination Study of AZD5069 and Enzalutamide. [Phase 1, Phase 2]
A phase 1/2 combination trial of AZD5069 with Enzalutamide in metastatic castration-resistant prostate cancer was terminated.
-
CLINICAL_TRIALS trial_result · 2024-09-25Clinical Trial Update: Addition of Opaganib to Androgen Antagonists in Patients With mCRPC [Phase 2]
Phase 2 trial results evaluating the addition of opaganib to androgen antagonists in patients with metastatic castration-resistant prostate …